Lung Cancer | Specialty

Dr. Perol on EGFR TKI/Chemotherapy Combinations in Advanced EGFR+ NSCLC

November 21st 2020

Maurice Perol, MD, discusses combination regimens comprised of chemotherapy and EGFR TKIs in the treatment of patients with EGFR-mutated advanced non–small cell lung cancer, as investigated in the OPAL trial presented during the ESMO Asia Virtual Congress 2020.

Dr. Chaft on the Next Steps of Osimertinib Research in EGFR+ NSCLC

November 20th 2020

Jamie E. Chaft, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps of osimertinib research in EGFR-mutant non–small cell lung cancer.

Dr. Tsuboi on Findings From the Phase 3 ADAURA Trial in EGFR+ NSCLC

November 20th 2020

Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses findings from the phase 3 ADAURA trial in EGFR-mutant non–small cell lung cancer.

Osimertinib Plus Chemotherapy Is Well Tolerated in Frontline EGFR+ NSCLC

November 20th 2020

November 20, 2020 - Osimertinib in combination with platinum plus pemetrexed was well tolerated in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer.

Prognostic Identifiers for ES-SCLC Are Not Revealed in CASPIAN Subgroup Analysis

November 20th 2020

November 20, 2020 - Exploratory subgroup analysis of patients with extensive-stage small-cell lung cancer who derived a progression-free survival benefit with durvalumab plus platinum-based chemotherapy lasting longer than 12 months in the CASPIAN trial did not reveal any clinical characteristics that could serve as predictive factors for benefit with the monoclonal antibody.

FDA Approves Durvalumab for Fixed-Dose Use in NSCLC, Bladder Cancer Indications

November 20th 2020

November 20, 2020 - The FDA has approved durvalumab for an additional dosing option, a fixed dose of 1500 mg every 4 weeks, in the approved indications of unresectable stage III non-small cell lung cancer after chemoradiation and previously treated advanced bladder cancer.

Future Efforts Focused on Optimizing TKI Use Across the Continuum of Care for EGFR+ NSCLC

November 19th 2020

Kristen A. Marrone, MD, discusses research efforts with osimertinib in EGFR-mutated lung cancer, overcoming resistance to the agent, and optimizing sequential molecular testing.

Lorlatinib Data Published in NEJM Underscore Benefits Over Crizotinib in ALK+ NSCLC

November 19th 2020

November 19, 2020 - Lorlatinib has been found to significantly prolong progression-free survival, elicit a higher overall and intracranial response, and improve quality of life compared with crizotinib in treatment-naïve patients with advanced ALK-positive non­–small cell lung cancer.

METex14+ NSCLC Armamentarium Welcomes First Targeted Therapy

November 19th 2020

The first biomarker-drive intervention for patients with non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation is now available in clinical practice.

Dr. Rizvi on the Rationale to Evaluate Telaglenastat in KEAP1/NRF2-Mutant NSCLC

November 18th 2020

Naiyer A. Rizvi, MD, discusses the rationale to evaluate the investigational glutaminase inhibitor telaglenastat in patients with non–small cell lung cancer who harbor KEAP1 or NRF2 mutations.

Rapid Readouts: Phase 1/2 KRYSTAL-1 Trial

November 18th 2020

Dr. Subramanian on the Potential Utility of Dostarlimab in Previously Treated NSCLC

November 17th 2020

Janakiraman Subramanian, MD, discusses the potential utility of dostarlimab in ​previously treated patients with non–small cell lung cancer.

Dr. Ramalingam on Limitations With Immunotherapy in NSCLC

November 17th 2020

Suresh S. Ramalingam, MD, FASCO, discusses limitations with immunotherapy in non–small cell lung cancer.

Tislelizumab Improves Survival in Second- or Third-Line NSCLC

November 17th 2020

November 17, 2020 - The PD-1 inhibitor tislelizumab was found to improve overall survival versus docetaxel in the second- or third-line treatment in patients with locally advanced or metastatic non–small cell lung cancer who progressed on previous platinum-based chemotherapy.

Raez Raises Concerns Over Delayed Cancer Care in the COVID-19 Era

November 16th 2020

In our exclusive interview, Dr. Raez discusses the reasons for the declines in routine screening and referrals due to the coronavirus disease 2019, anticipated consequences, and some of the ways in which the health care community can combat these newfound challenges.

Next Steps for RET-Mutated Medullary Thyroid Cancer

November 16th 2020

Recent Approval of Selpercatinib in RET-Mutated MTC

November 16th 2020

Multikinase TKIs in Medullary Thyroid Cancer

November 16th 2020

Actionable Driver Mutations in Medullary Thyroid Cancer

November 16th 2020

Epidemiology of Medullary Thyroid Cancer

November 16th 2020